Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash from Operations (2019 - 2025)

Burning Rock Biotech has reported Cash from Operations over the past 7 years, most recently at 3293000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 26.12% year-over-year to 3293000.0; the TTM value through Dec 2025 reached 7121000.0, up 70.86%, while the annual FY2025 figure was 4068000.0, 67.82% up from the prior year.
  • Cash from Operations for Q4 2025 was 3293000.0 at Burning Rock Biotech, up from 2303000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 3293000.0 in Q4 2025 and troughed at 22772000.0 in Q1 2022.
  • A 5-year average of 10469994.01 and a median of 10221440.14 in 2022 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: tumbled 1632.5% in 2021 and later soared 215.74% in 2024.
  • Year by year, Cash from Operations stood at 17628000.0 in 2021, then surged by 46.0% to 9519880.29 in 2022, then surged by 76.3% to 2256000.0 in 2023, then soared by 215.74% to 2611000.0 in 2024, then rose by 26.12% to 3293000.0 in 2025.
  • Business Quant data shows Cash from Operations for BNR at 3293000.0 in Q4 2025, 2303000.0 in Q3 2025, and 9475000.0 in Q2 2025.